Core Viewpoint - Hualan Co., Ltd. is expanding its strategic footprint in the AI-driven drug development sector through a capital increase agreement with several biotech firms, indicating a commitment to align with national strategies and enhance its technological capabilities in this emerging field [1] Group 1: Investment Details - Hualan's wholly-owned subsidiary, Lingqing Zhizhi, has signed a capital increase agreement with Shenzhen Jingtai and other companies to invest in Kema Biotechnology [1] - Lingqing Zhizhi plans to use its own funds of 20 million yuan to subscribe to the newly increased registered capital of Kema Biotechnology, acquiring a 9.53% stake on a fully diluted basis [1] - Following the agreement, Lingqing Zhizhi will secure a board seat at Kema Biotechnology and gain a preferential right to acquire shares under the same conditions [1] Group 2: Company Background - Kema Biotechnology, established in 2021, focuses on antibody design using generative AI models and is incubated by the leading AI innovative drug development company, Jingtai Holdings [1] Group 3: Strategic Implications - This investment marks a significant step for Hualan Co., Ltd. in responding to national strategies and solidifying its presence in the AI innovative drug development sector [1] - The company aims to deepen its engagement in AI drug research and development by attracting top industry experts and building a diversified business team to enhance its technical service capabilities [1]

Group 1: China Construction - The total new contracts signed by China Construction from January to October reached 3.61 trillion yuan, representing a year-on-year increase of 1% [1] Group 2: Changyuan Power - Changyuan Power's subsidiary received approval for the 100MW wind power project in Songzi, Hubei [2] Group 3: China Metallurgical Group - China Metallurgical Group reported a total new contract amount of 845.07 billion yuan from January to October, a decrease of 11.8% year-on-year, while overseas contracts increased by 7.3% to 71.16 billion yuan [4] Group 4: Shapuaisi - Shapuaisi received approval for clinical trials of deoxycorticosterone ketone solution, intended for use during cataract surgery [5] Group 5: Jianfeng Group - Jianfeng Group's subsidiary received approval for clinical trials of a new drug for treating advanced non-squamous non-small cell lung cancer [7] Group 6: Chongqing Steel - Chongqing Steel announced the resignation of its president Meng Wenwang due to work adjustments [8] Group 7: Tianma Technology - Tianma Technology reported an output of approximately 1732.99 tons of eel in October, with a total output of about 15218.73 tons from January to October [10] Group 8: Qingyuan Co. - Qingyuan Co.'s controlling shareholder reduced holdings of convertible bonds by 685,400 units, accounting for 13.71% of the total issuance [11] Group 9: Spring Airlines - Spring Airlines reported a passenger turnover of 506,200.49 million kilometers in October, a year-on-year increase of 20.06% [12] Group 10: China Merchants Port - China Merchants Port reported a total container volume of 17.1714 million TEUs from January to October, a year-on-year increase of 5.1% [13] Group 11: Yangdian Technology - Yangdian Technology announced a change in control following a share transfer [15] Group 12: Wanfu Biology - Wanfu Biology decided to postpone the implementation of its Knowledge City production base project [16] Group 13: Iwu Biology - Iwu Biology terminated the research project for a specific drug, which will reduce its 2025 net profit by approximately 333.79 million yuan [17] Group 14: Hainan Rubber - Hainan Rubber received an insurance payout of 22.9241 million yuan due to revenue loss from rubber price fluctuations [19] Group 15: Xinjiang Tianye - Xinjiang Tianye plans to establish a joint venture with Tianchi Energy to develop coal chemical projects [20] Group 16: China Coal Energy - China Coal Energy's executive director and president Zhao Rongzhe resigned due to reaching retirement age [22] Group 17: Huading Co. - Huading Co. received approval for a stock issuance to specific investors from the Shanghai Stock Exchange [24] Group 18: Zhongmu Co. - Zhongmu Co. decided to waive its right of first refusal for a 4.04% stake in a subsidiary [25] Group 19: Tianlong Co. - Tianlong Co. reported that its subsidiary's stock issuance was approved by the Beijing Stock Exchange [26] Group 20: Hualan Co. - Hualan Co.'s subsidiary plans to invest 20 million yuan in a biotechnology company [27] Group 21: Haichen Pharmaceutical - Haichen Pharmaceutical received a drug registration certificate for a new injection [28] Group 22: Aier Eye Hospital - Aier Eye Hospital plans to invest 300 million yuan in wealth management products [29] Group 23: Xiamen Engineering Machinery - Xiamen Engineering Machinery announced a planned share reduction by a major shareholder [30] Group 24: Guotai Group - Guotai Group successfully acquired 100% of a mining technology company for 110.1 million yuan [31] Group 25: Wanfeng Aowei - Wanfeng Aowei reached a settlement regarding an arbitration matter with a subsidiary [32] Group 26: Taihe Technology - Taihe Technology is undergoing technical upgrades for its ethylene carbonate project [33] Group 27: Renhe Pharmaceutical - Renhe Pharmaceutical's controlling shareholder plans to reduce holdings by 0.21% [34] Group 28: Changshu Bank - Changshu Bank's second-largest shareholder increased its stake to 3.98% [35] Group 29: Overseas Chinese Town A - Overseas Chinese Town A reported a 57% decrease in contract sales in October [36] Group 30: Canadian Solar - Canadian Solar's controlling shareholder expects total revenue of 1.3 to 1.5 billion USD in Q4 2025 [38] Group 31: Zhonggong Education - Zhonggong Education's controlling shareholder's shares will be auctioned due to a loan dispute [40] Group 32: Aikexibo - Aikexibo's shareholders plan to reduce their holdings by up to 3% [42] Group 33: Wanhua Chemical - Wanhua Chemical's shareholder plans to reduce holdings by up to 0.5% [44] Group 34: Jujie Microfiber - Jujie Microfiber's controlling shareholder plans to reduce holdings by up to 2% [45] Group 35: Wangsu Technology - Wangsu Technology's shareholder plans to reduce holdings by up to 1% [46] Group 36: Tianli Lithium Energy - Tianli Lithium Energy received a patent for lithium-ion battery materials [47] Group 37: Heshun Electric - Heshun Electric won a 40 million yuan project for energy storage services [49] Group 38: Changchun High-tech - Changchun High-tech's subsidiary received FDA approval for a clinical trial of a new drug [51] Group 39: Dongrui Co. - Dongrui Co. received an additional export quota for live pigs to Hong Kong [52] Group 40: Zhongwei Co. - Zhongwei Co. set the H-share issuance price at 34 HKD per share [53] Group 41: Fospower Technology - Fospower Technology plans to invest in a lithium sulfide project with partners [54]

灵擎数智与深圳晶泰拟共同向科迈生物进行增资入股。其中，灵擎数智计划使用自有资金人民币2,000 万元认购科迈生物新增的注册资本，进一步取得本次交易后科迈生物基于完全摊薄基础上9.53%的股权 (对应于本次交易完成后科迈生物人民币296,296元的注册资本，剩余计入科迈生物资本公积)。 公告称，全球AI创新药研发领域正蓬勃发展，在这一趋势下，中国也亟需培育具备国际竞争力的本土 AI创新药研发企业，以积极参与全球医药创新的新一轮竞争。《中共中央关于制定国民经济和社会发 展第十五个五年规划的建议》，明确深入推进数字中国建设，全面实施"人工智能+"行动。本次对外投 资系华兰股份响应国家战略、进入AI创新药研发领域战略布局落地的一步。 华兰股份（301093）(301093.SZ)发布公告，华兰股份全资子公司灵擎数智于近日与深圳晶泰、XtalPi、 晶泰智启、科迈生物、科迈数抗以及持股平台签署了增资协议。同时，灵擎数智与深圳晶泰、科迈生 物、科迈数抗、持股平台、XtalPi、晶泰智启、百奥赛图、Duckling、 Vibrant签署了股东协议。 科迈生物成立于2021年，是由全球领先AI创新药研发企业—晶泰控股孵化的一 ...

智通财经APP讯， 华兰股份(301093.SZ)发布公告，华兰股份全资子公司灵擎数智于近日与深圳晶泰、 XtalPi、晶泰智启、科迈生物、科迈数抗以及持股平台签署了增资协议。同时，灵擎数智与深圳晶泰、 科迈生物、科迈数抗、持股平台、XtalPi、晶泰智启、百奥赛图、Duckling、 Vibrant签署了股东协议。 灵擎数智与深圳晶泰拟共同向科迈生物进行增资入股。其中，灵擎数智计划使用自有资金人民币2,000 万元认购科迈生物新增的注册资本，进一步取得本次交易后科迈生物基于完全摊薄基础上9.53%的股权 (对应于本次交易完成后科迈生物人民币296,296元的注册资本，剩余计入科迈生物资本公积)。 公告称，全球AI创新药研发领域正蓬勃发展，在这一趋势下，中国也亟需培育具备国际竞争力的本土 AI创新药研发企业，以积极参与全球医药创新的新一轮竞争。《中共中央关于制定国民经济和社会发 展第十五个五年规划的建议》，明确深入推进数字中国建设，全面实施"人工智能+"行动。本次对外投 资系华兰股份响应国家战略、进入AI创新药研发领域战略布局落地的一步。 科迈生物成立于2021年，是由全球领先AI创新药研发企业—晶泰控股孵化 ...

灵擎数智与深圳晶泰拟共同向科迈生物进行增资入股。其中，灵擎数智计划使用自有资金人民币2,000 万元认购科迈生物新增的注册资本，进一步取得本次交易后科迈生物基于完全摊薄基础上9.53%的股权 （对应于本次交易完成后科迈生物人民币296,296元的注册资本，剩余计入科迈生物资本公积）。本次 协议签署完成后，灵擎数智将获得科迈生物一席董事会席位以及在同等条件下对科迈生物的优先收购 权。 格隆汇11月14日丨华兰股份(301093.SZ)公布，华兰股份全资子公司灵擎数智于近日与深圳晶泰、 XtalPi、晶泰智启、科迈生物、科迈数抗以及持股平台签署了增资协议。同时，灵擎数智与深圳晶泰、 科迈生物、科迈数抗、持股平台、XtalPi、晶泰智启、百奥赛图、Duckling、Vibrant签署了股东协议。 科迈生物成立于2021年，是由全球领先AI创新药研发企业—晶泰控股孵化的一家专注于利用生成式AI 模型进行抗体设计的生物科技企业。公司依托于内部湿实验产生的数百万对自有的高质量抗体-抗原配 对数据，依托自研的AI抗体设计算法与AI智能体等深度学习技术，面向抗体药物研发的核心需求，打 造出高效、精准的AI抗体设计平台。科迈生 ...

人民财讯11月14日电，华兰股份（301093）11月13日公告，华兰股份全资子公司灵擎数智与深圳晶泰拟 共同向科迈生物科技(苏州)有限公司(简称"科迈生物")进行增资入股。其中，灵擎数智计划使用2000万 元认购科迈生物新增的注册资本，进一步取得此次交易后科迈生物基于完全摊薄基础上9.53%的股权。 交易完成后，灵擎数智将获得科迈生物一席董事会席位以及在同等条件下对科迈生物的优先收购权。 科迈生物成立于2021年，是由全球领先AI创新药研发企业晶泰控股孵化的一家专注于利用生成式AI模 型进行抗体设计的生物科技企业。 ...

证券代码：301093 证券简称：华兰股份 公告编号：2025-114 | 华兰股份 | 指 | 江苏华兰药用新材料股份有限公司 | | --- | --- | --- | | 灵擎数智 | 指 | 海南灵擎数智医药科技有限公司 | | 深圳晶泰 | 指 | 深圳晶泰科技有限公司 | | XtalPi | 指 | XtalPi Investment Limited | | 晶泰智启 | 指 | 晶泰智启星图（苏州）生物科技有限公司 | | 公司、科迈生物 | 指 | 科迈生物科技（苏州）有限公司 | | 科迈数抗 | 指 | 科迈数抗生物科技（北京）有限公司 | | 持股平台 | 指 | 苏州科迈生物医药科技合伙企业（有限合伙） | | 百奥赛图 | 指 | 百奥赛图（北京）医药科技股份有限公司 | | Duckling | 指 | Duckling Fund, L.P. | | Vibrant | 指 | Vibrant Evolution II Limited 沃依二期有限公司 | | 增资协议、本协议 | 指 | 《关于科迈生物科技（苏州）有限公司之增资协议》 | | 股东协议 | 指 | 《关于科迈生 ...

华兰股份涨2.78%，报47.0元/股，股价再创新高，总市值突破77.17亿元，成交额达1.13亿元。（AI生 成） ...

Market Overview - The medical device sector experienced a slight increase of 0.04% on November 13, with Hotgen Biotech leading the gains [1] - The Shanghai Composite Index closed at 4029.5, up 0.73%, while the Shenzhen Component Index closed at 13476.52, up 1.78% [1] Top Gainers - Hotgen Biotech (688068) closed at 170.15, with a significant increase of 11.36% and a trading volume of 59,400 shares [1] - Jikang Development (600807) saw a rise of 9.92%, closing at 3.88 with a trading volume of 561,900 shares [1] - Hualan Biological Engineering (301093) increased by 8.35%, closing at 49.55 with a trading volume of 77,300 shares [1] - Other notable gainers include Baijun Medical (688198) up 6.14% and Wuzhou Medical (301234) up 4.43% [1] Top Losers - Yuanpeng Medical (300753) experienced a decline of 6.35%, closing at 28.76 with a trading volume of 150,800 shares [2] - Zhend Medical (603301) fell by 2.93%, closing at 88.04 with a trading volume of 82,900 shares [2] - Other significant declines include Kefu Medical (301087) down 2.73% and Canar Co. (301122) down 2.71% [2] Capital Flow - The medical device sector saw a net outflow of 937 million yuan from institutional investors, while retail investors contributed a net inflow of 722 million yuan [2] - The overall capital flow indicates a mixed sentiment, with institutional investors pulling back while retail investors remain active [2] Individual Stock Capital Flow - Jikang Development had a net inflow of 47.75 million yuan from institutional investors, while retail investors showed a net outflow of 36.24 million yuan [3] - Hualan Biological Engineering recorded a net inflow of 44.30 million yuan from institutional investors, with retail investors experiencing a net outflow of 47.73 million yuan [3] - Other stocks like Sanxin Medical (300453) and Wuzhou Medical (301234) also showed varied capital flows, reflecting differing investor sentiments [3]

Group 1 - The core viewpoint of the news is that Hualan Co., Ltd. has seen a stock price increase of 5.03%, reaching 48.03 CNY per share, with a total market capitalization of 7.887 billion CNY [1] - Hualan Co., Ltd. specializes in the research, production, and sales of packaging materials for injectable drugs, with its main revenue sources being film-coated rubber stoppers (49.07%) and conventional rubber stoppers (48.50%) [1] - The company is located in Jiangyin City, Jiangsu Province, and was established on June 4, 1992, with its listing date on November 1, 2021 [1] Group 2 - From the perspective of fund holdings, Hualan Co., Ltd. is a significant investment for the Galaxy Fund, with the Galaxy Kangle Stock A fund reducing its holdings by 130,300 shares in the third quarter, now holding 225,500 shares, which constitutes 4.88% of the fund's net value [2] - The Galaxy Kangle Stock A fund has achieved a year-to-date return of 27.43% and a one-year return of 17.49%, ranking 1963 out of 4216 and 2252 out of 3951 respectively among its peers [2] - The fund manager, Fang Wei, has been in charge for 4 years and 189 days, with the fund's total asset size currently at 703 million CNY [3]